Policy guide
Prescriber's Guide to the HHS Peptide Policy
What the policy covers, what a pharmacy has to do to qualify, and what to ask before you prescribe.
Read the prescriber's guidePolicy update: HHS enforcement discretion now covers six compounded peptides for individual patients. Empower is bringing all six to our formulary.
Compounded peptide updates from Empower Pharmacy
Your patients are already asking about peptides. Start with prescriber guides and policy news from the PCAB-accredited pharmacy behind the prescription.
PCAB-accredited 503A pharmacy.
LegitScript certified.
Start Here
The regulatory landscape is evolving. These resources keep your practice ahead of it.
Policy guide
What the policy covers, what a pharmacy has to do to qualify, and what to ask before you prescribe.
Read the prescriber's guideReference
Form, route and status for each of the six peptides named in the HHS policy.
Open the covered peptides matrixKnowledge Center
Provider-focused articles and resources on peptide compounding, in one place.
Browse peptide resourcesRelated questions
More from Empower:
Stay informed
Policy updates and prescriber guides for your practice, plus a notice when peptide availability changes.
Compounded medications require a prescription and are not FDA-approved. Availability depends on federal and state requirements. This form does not place an order.
TELL US WHO YOU ARE:
Thank you!
We can serve patients from our 503A pharmacy with a prescription. Talk to your provider about prescribing with us. We look forward to serving you.
Peptide line-up
The six peptides now covered under the HHS policy: the routes the policy covers for each, and the formulations we compound.
Six HHS-covered peptides
HHS covered routesSubcutaneous, intramuscular, oral, topical
Empower formulationsCapsule 500 mcg and 1,000 mcg · Troche 1,000 mcg · Injection 3 mg/mL
HHS covered routesSubcutaneous, intramuscular
Empower formulationsInjection 3 mg/mL
HHS covered routesSubcutaneous, intramuscular
Empower formulationsInjection 2 mg/mL
HHS covered routesSubcutaneous, intramuscular, in intermittent courses
Empower formulationsInjection 10 mg/mL
HHS covered routesIntranasal
Empower formulationsNasal spray 7.5 mg/mL
HHS covered routesTopical, oral
Empower formulationsCapsule 500 mcg
Also on our formulary: GHK-Cu (capsule, scalp solution and facial serum), Sermorelin injection, Gonadorelin injection.
Peptide stacks
Each peptide is its own single-ingredient prescription, in line with the HHS policy. Write a prescription for each, and we'll dispense each as its own labeled product, shipped together.
Includes
Includes
Includes
Also available: the metabolic stack (MOTS-c with the tirzepatide / niacinamide injection) and a BPC-157 and KPV capsule bundle.
Pricing and state availability vary by product.
Request Pricing & InformationCompounded medications require a prescription and are not FDA-approved. The HHS policy is interim enforcement discretion, not approval, and may change. Availability depends on federal and state requirements. Routes shown are those covered by the policy for each substance; Empower offers the formulations listed.
Why partner with Empower
When patients are counting on you, count on us.
Every peptide we compound moves through the same quality system behind everything we make. Three more reasons providers partner with us.
01
Capacity for a national platform, attention for a single practice
Licensed across the country, with the capacity to serve a single practice or a national platform.
02
You see what the price covers
Qualified sourcing, release testing, pharmacist oversight. The price reflects the process.
03
Easy to start, supported from day one
Prescribe the way you already do, with an account team and pharmacists to support your patients' needs.
FAQ
Answers about how Empower sources, tests and supports peptide prescriptions.
Policy questions? The prescriber's guide to the HHS peptide policy answers them, and the covered peptides matrix shows form and route for each peptide.
HHS’s peptide enforcement discretion policy is a statement that it does not intend to take enforcement action against certain peptide compounding when specific conditions are met. It is a draft interim policy that is not binding on HHS or the public, and it does not change Section 503A. The policy stays in place while FDA builds the 503A bulk drug substances list through rulemaking.¹ It applies to state-licensed pharmacies, Federal facilities, and licensed physicians. A “licensed physician” here means one who compounds, not prescribers in general.
For prescribers, this changes the federal enforcement picture for the pharmacies you can work with, but it does not impact any state-specific laws or regulations that may exist in your state.
Six: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Each is limited to the specific form and routes listed. A peptide not on the list, or in a different form or route, is outside the policy.
Source: Appendix B of the HHS policy. Appendix B defines each peptide by exact sequence and formula. For instance, it describes TB-500 as a fragment of its parent protein, thymosin beta-4. The full text is in the Federal Register notice.
Yes. The policy names section 503A’s patient-specific prescription requirement as one of its conditions
The clinical decision for each patient is still yours. Consider documenting:
No. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. None of these six peptides is an FDA-approved drug.
HHS states that its policy is meant to expand patient access while FDA reviews these substances. Enforcement discretion describes how HHS intends to use its enforcement resources. It is not an approval of any peptide or compounded product.
An FDA-registered original manufacturer, with a Certificate of Analysis reviewed for each lot.
Each batch is released with a Certificate of Conformance. Prescribers can request it.
A Certificate of Conformance (COC) is Empower's batch-release document for a finished peptide; prescribers can request it. A Certificate of Analysis (COA) comes from the active ingredient manufacturer for each lot and, as reported, must show the manufacturer's location under the HHS policy. Confirm details in the policy text.
Sign up for updates on availability, regulatory changes, and educational resources from Empower.
Compounded medications are prescribed by licensed providers and prepared for individual patients. They are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are dispensed. This page makes no claims about the safety or efficacy of any product. Availability depends on federal and state requirements and may change. Serious adverse events and product-quality concerns are reported to FDA MedWatch and the state board, as the policy requires.
